Sepsis Treatment Market in China - Industry Outlook and Forecast 2020-2026

April 2020 | 102 pages | ID: SE543D0122B2EN
Market Monitor Global

Abstracts

Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.

This report contains market size and forecasts of Sepsis Treatment in China, including the following market information:
China Sepsis Treatment Market Revenue, 2015-2020, 2021-2026, ($ millions)
Top Five Competitors in China Sepsis Treatment Market 2019 (%)
The global Sepsis Treatment market was valued at 3007.8 million in 2019 and is projected to reach US$ 3858 million by 2026, at a CAGR of 6.4% during the forecast period. While the Sepsis Treatment market size in China was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.

COVID-19 pandemic has big impact on Sepsis Treatment businesses, with lots of challenges and uncertainty faced by many players of Sepsis Treatment in China. This report also analyses and evaluates the COVID-19 impact on Sepsis Treatment market size in 2020 and the next few years in China

Total Market by Segment:

China Sepsis Treatment Market, By Type, 2015-2020, 2021-2026 ($ millions)
China Sepsis Treatment Market Segment Percentages, By Type, 2019 (%)

• Cephalosporin
• Pencillin
• Macrolides
• Others

China Sepsis Treatment Market, By Application, 2015-2020, 2021-2026 ($ millions)
China Sepsis Treatment Market Segment Percentages, By Application, 2019 (%)

• Sepsis
• Severe Sepsis
• Septic Shock

Competitor Analysis

The report also provides analysis of leading market participants including:
Total Sepsis Treatment Market Competitors Revenues in China, by Players 2015-2020 (Estimated), ($ millions)
Total Sepsis Treatment Market Competitors Revenues Share in China, by Players 2019 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Pfizer
• NCPC
• Bayer
• Shanghai Pharmaceuticals
• Johnson & Johnson
• Novartis
• GlaxoSmithKline
• TEVA
• Mylan
• Allergan
• Merck & Co
• Asahi Kasei Corporation
• AtoxBio
• INOTREM
• Adrenomed

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Sepsis Treatment Market Definition
1.2 Market Segments
  1.2.1 Segment by Type
  1.2.2 Segment by Application
1.3 COVID-19 Impact: China Sepsis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 CHINA SEPSIS TREATMENT OVERALL MARKET SIZE

2.1 China Sepsis Treatment Market Size: 2020 VS 2026
2.2 China Sepsis Treatment Revenue, Prospects & Forecasts: 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Sepsis Treatment Players in China (including Foreign and Local Companies)
3.2 Top China Sepsis Treatment Companies Ranked by Revenue
3.3 China Sepsis Treatment Revenue by Companies (including Foreign and Local Companies)
3.4 Top 3 and Top 5 Sepsis Treatment Companies in China, by Revenue in 2019
3.5 China Manufacturers Sepsis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Sepsis Treatment Players in China
  3.6.1 List of China Tier 1 Sepsis Treatment Companies
  3.6.2 List of China Tier 2 and Tier 3 Sepsis Treatment Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - China Sepsis Treatment Market Size Markets, 2020 & 2026
  4.1.2 Cephalosporin
  4.1.3 Pencillin
  4.1.4 Macrolides
  4.1.5 Others
4.2 By Type - China Sepsis Treatment Revenue & Forecasts
  4.2.1 By Type - China Sepsis Treatment Revenue, 2015-2020
  4.2.2 By Type - China Sepsis Treatment Revenue, 2021-2026
  4.2.3 By Type - China Sepsis Treatment Revenue Market Share, 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - China Sepsis Treatment Market Size, 2020 & 2026
  5.1.2 Sepsis
  5.1.3 Severe Sepsis
  5.1.4 Septic Shock
5.2 By Application - China Sepsis Treatment Revenue & Forecasts
  5.2.1 By Application - China Sepsis Treatment Revenue, 2015-2020
  5.2.2 By Application - China Sepsis Treatment Revenue, 2021-2026
  5.2.3 By Application - China Sepsis Treatment Revenue Market Share, 2015-2026

6 PLAYERS PROFILES

6.1 Pfizer
  6.1.1 Pfizer Corporate Summary
  6.1.2 Pfizer Business Overview
  6.1.3 Pfizer Sepsis Treatment Major Product Offerings
  6.1.4 Pfizer Revenue in China (2015-2020)
  6.1.5 Pfizer Key News
6.2 NCPC
  6.2.1 NCPC Corporate Summary
  6.2.2 NCPC Business Overview
  6.2.3 NCPC Sepsis Treatment Major Product Offerings
  6.2.4 NCPC Revenue in China (2015-2020)
  6.2.5 NCPC Key News
6.3 Bayer
  6.3.1 Bayer Corporate Summary
  6.3.2 Bayer Business Overview
  6.3.3 Bayer Sepsis Treatment Major Product Offerings
  6.3.4 Bayer Revenue in China (2015-2020)
  6.3.5 Bayer Key News
6.4 Shanghai Pharmaceuticals
  6.4.1 Shanghai Pharmaceuticals Corporate Summary
  6.4.2 Shanghai Pharmaceuticals Business Overview
  6.4.3 Shanghai Pharmaceuticals Sepsis Treatment Major Product Offerings
  6.4.4 Shanghai Pharmaceuticals Revenue in China (2015-2020)
  6.4.5 Shanghai Pharmaceuticals Key News
6.5 Johnson & Johnson
  6.5.1 Johnson & Johnson Corporate Summary
  6.5.2 Johnson & Johnson Business Overview
  6.5.3 Johnson & Johnson Sepsis Treatment Major Product Offerings
  6.5.4 Johnson & Johnson Revenue in China (2015-2020)
  6.5.5 Johnson & Johnson Key News
6.6 Novartis
  6.6.1 Novartis Corporate Summary
  6.6.2 Novartis Business Overview
  6.6.3 Novartis Sepsis Treatment Major Product Offerings
  6.6.4 Novartis Revenue in China (2015-2020)
  6.6.5 Novartis Key News
6.7 GlaxoSmithKline
  6.6.1 GlaxoSmithKline Corporate Summary
  6.6.2 GlaxoSmithKline Business Overview
  6.6.3 GlaxoSmithKline Sepsis Treatment Major Product Offerings
  6.4.4 GlaxoSmithKline Revenue in China (2015-2020)
  6.7.5 GlaxoSmithKline Key News
6.8 TEVA
  6.8.1 TEVA Corporate Summary
  6.8.2 TEVA Business Overview
  6.8.3 TEVA Sepsis Treatment Major Product Offerings
  6.8.4 TEVA Revenue in China (2015-2020)
  6.8.5 TEVA Key News
6.9 Mylan
  6.9.1 Mylan Corporate Summary
  6.9.2 Mylan Business Overview
  6.9.3 Mylan Sepsis Treatment Major Product Offerings
  6.9.4 Mylan Revenue in China (2015-2020)
  6.9.5 Mylan Key News
6.10 Allergan
  6.10.1 Allergan Corporate Summary
  6.10.2 Allergan Business Overview
  6.10.3 Allergan Sepsis Treatment Major Product Offerings
  6.10.4 Allergan Revenue in China (2015-2020)
  6.10.5 Allergan Key News
6.11 Merck & Co
  6.11.1 Merck & Co Corporate Summary
  6.11.2 Merck & Co Sepsis Treatment Business Overview
  6.11.3 Merck & Co Sepsis Treatment Major Product Offerings
  6.11.4 Merck & Co Revenue in China (2015-2020)
  6.11.5 Merck & Co Key News
6.12 Asahi Kasei Corporation
  6.12.1 Asahi Kasei Corporation Corporate Summary
  6.12.2 Asahi Kasei Corporation Sepsis Treatment Business Overview
  6.12.3 Asahi Kasei Corporation Sepsis Treatment Major Product Offerings
  6.12.4 Asahi Kasei Corporation Revenue in China (2015-2020)
  6.12.5 Asahi Kasei Corporation Key News
6.13 AtoxBio
  6.13.1 AtoxBio Corporate Summary
  6.13.2 AtoxBio Sepsis Treatment Business Overview
  6.13.3 AtoxBio Sepsis Treatment Major Product Offerings
  6.13.4 AtoxBio Revenue in China (2015-2020)
  6.13.5 AtoxBio Key News
6.14 INOTREM
  6.14.1 INOTREM Corporate Summary
  6.14.2 INOTREM Sepsis Treatment Business Overview
  6.14.3 INOTREM Sepsis Treatment Major Product Offerings
  6.14.4 INOTREM Revenue in China (2015-2020)
  6.14.5 INOTREM Key News
6.15 Adrenomed
  6.15.1 Adrenomed Corporate Summary
  6.15.2 Adrenomed Sepsis Treatment Business Overview
  6.15.3 Adrenomed Sepsis Treatment Major Product Offerings
  6.15.4 Adrenomed Revenue in China (2015-2020)
  6.15.5 Adrenomed Key News
6.16 Endacea
  6.16.1 Endacea Corporate Summary
  6.16.2 Endacea Sepsis Treatment Business Overview
  6.16.3 Endacea Sepsis Treatment Major Product Offerings
  6.16.4 Endacea Revenue in China (2015-2020)
  6.16.5 Endacea Key News

7 KEY MARKET TRENDS & INFLUENCES 2021-2026

7.1 PESTLE Analysis for China Sepsis Treatment Market
7.2 Market Opportunities & Trends
7.3 Market Drivers
7.4 Market Restraints

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Sepsis Treatment in China
Table 2. Top Players in China, Ranking by Revenue (2019)
Table 3. China Sepsis Treatment Revenue by Companies, (US$, Mn), 2015-2020
Table 4. China Sepsis Treatment Revenue Share by Companies, 2015-2020
Table 5. China Sepsis Treatment Sales by Companies, (K Units), 2015-2020
Table 6. China Sepsis Treatment Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Sepsis Treatment Price (2015-2020) (US$/Unit)
Table 8. China Manufacturers Sepsis Treatment Product Type
Table 9. List of China Tier 1 Sepsis Treatment Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of China Tier 2 and Tier 3 Sepsis Treatment Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Sepsis Treatment Revenue in China (US$, Mn), 2015-2020
Table 12. By Type - Sepsis Treatment Revenue in China (US$, Mn), 2021-2026
Table 13. By Type - Sepsis Treatment Sales in China (K Units), 2015-2020
Table 14. By Type - Sepsis Treatment Sales in China (K Units), 2021-2026
Table 15. By Application - Sepsis Treatment Revenue in China, (US$, Mn), 2015-2020
Table 16. By Application - Sepsis Treatment Revenue in China, (US$, Mn), 2021-2026
Table 17. By Application - Sepsis Treatment Sales in China, (K Units), 2015-2020
Table 18. By Application - Sepsis Treatment Sales in China, (K Units), 2021-2026
Table 19. Pfizer Corporate Summary
Table 20. Pfizer Sepsis Treatment Product Offerings
Table 21. Pfizer Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 22. NCPC Corporate Summary
Table 23. NCPC Sepsis Treatment Product Offerings
Table 24. NCPC Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 25. Bayer Corporate Summary
Table 26. Bayer Sepsis Treatment Product Offerings
Table 27. Bayer Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 28. Shanghai Pharmaceuticals Corporate Summary
Table 29. Shanghai Pharmaceuticals Sepsis Treatment Product Offerings
Table 30. Shanghai Pharmaceuticals Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 31. Johnson & Johnson Corporate Summary
Table 32. Johnson & Johnson Sepsis Treatment Product Offerings
Table 33. Johnson & Johnson Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 34. Novartis Corporate Summary
Table 35. Novartis Sepsis Treatment Product Offerings
Table 36. Novartis Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 37. GlaxoSmithKline Corporate Summary
Table 38. GlaxoSmithKline Sepsis Treatment Product Offerings
Table 39. GlaxoSmithKline Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 40. TEVA Corporate Summary
Table 41. TEVA Sepsis Treatment Product Offerings
Table 42. TEVA Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 43. Mylan Corporate Summary
Table 44. Mylan Sepsis Treatment Product Offerings
Table 45. Mylan Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 46. Allergan Corporate Summary
Table 47. Allergan Sepsis Treatment Product Offerings
Table 48. Allergan Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 49. Merck & Co Corporate Summary
Table 50. Merck & Co Sepsis Treatment Product Offerings
Table 51. Merck & Co Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 52. Asahi Kasei Corporation Corporate Summary
Table 53. Asahi Kasei Corporation Sepsis Treatment Product Offerings
Table 54. Asahi Kasei Corporation Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 55. AtoxBio Corporate Summary
Table 56. AtoxBio Sepsis Treatment Product Offerings
Table 57. AtoxBio Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 58. INOTREM Corporate Summary
Table 59. INOTREM Sepsis Treatment Product Offerings
Table 60. INOTREM Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 61. Adrenomed Corporate Summary
Table 62. Adrenomed Sepsis Treatment Product Offerings
Table 63. Adrenomed Sepsis Treatment Revenue (US$, Mn), (2015-2020)
Table 64. Endacea Corporate Summary
Table 65. Endacea Sepsis Treatment Product Offerings
Table 66. Endacea Sepsis Treatment Revenue (US$, Mn), (2015-2020)

List Of Figures

LIST OF FIGURES

Figure 1. Sepsis Treatment Segment by Type
Figure 2. Sepsis Treatment Segment by Application
Figure 3. China Sepsis Treatment Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Sepsis Treatment Market Size in China, (US$, Mn): 2020 VS 2026
Figure 6. China Sepsis Treatment Revenue, 2015-2026 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Sepsis Treatment Revenue in 2019
Figure 8. By Type - China Sepsis Treatment Incremental Growth, (US$, Mn), 2015-2026
Figure 9. By Type - China Sepsis Treatment Market Share, 2015-2026
Figure 10. By Application - Sepsis Treatment Revenue in China (US$, Mn), 2020 & 2026
Figure 11. By Application - China Sepsis Treatment Market Share, 2015-2026
Figure 12. PEST Analysis for China Sepsis Treatment Market in 2020
Figure 13. Sepsis Treatment Market Opportunities & Trends in China
Figure 14. Sepsis Treatment Market Drivers in China